

Top Trend In kanuma Market 2025: Enzyme Replacement Therapy (ERT) Drives Growth, With NHS Approval For Wolman Disease

The Business Research Company's Kanuma Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 8, 2025 /EINPresswire.com/ -- What Has Been the Growth Rate of the Kanuma Market in Recent Years?



The Kanuma market has experienced significant growth in recent years, demonstrating a strong historic compound annual growth rate (HCAGR).

• The market size, valued at \$XX million in 2024, is expected to expand to \$XX million in 2025.

rate (CAGR) of XX%.

"

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The Business Research

company

Increased awareness of rare genetic disorders.
A rise in pediatric lysosomal acid lipase deficiency (LAL-

• Key factors driving this expansion include:

D) cases.

o Broad regulatory approval for enzyme replacement therapies such as Kanuma.

• This growth corresponds to a compound annual growth

o Improved healthcare infrastructure, particularly in emerging markets.

o Expansion of insurance coverage for rare disease

treatments.

Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=20121&type=smp

What Is the Future Outlook for the Kanuma Market?

The Kanuma market is projected to continue its upward trajectory, reflecting strong demand and increasing research investments.

- The Kanuma market size is anticipated to rise from \$XX million in 2025 to \$XX million by 2029.
- This represents a compound annual growth rate (CAGR) of XX%.
- Factors contributing to this projected growth include:
- o Expanding demand for personalized medicine.
- o Greater focus on early diagnosis and treatment of rare diseases.
- o Rising prevalence of genetic disorders worldwide.
- o Strong governmental support for orphan drug development.
- o Enhanced awareness campaigns targeted at patients and healthcare professionals.
- Notable trends influencing the market:
- o Advancements in diagnostic technologies for LAL-D.
- o Innovations in enzyme therapy and biotechnology.
- o Growing collaborations between biotech firms and health authorities.
- o The development of combination therapies for rare diseases.

Order Your Report Now For A Swift Delivery

https://www.thebusinessresearchcompany.com/report/kanuma-global-market-report

What Are the Key Drivers of Growth in the Kanuma Market?

A primary catalyst for the Kanuma market is the increasing incidence of lysosomal acid lipase deficiency (LAL-D), a rare genetic condition leading to lipid accumulation in organs and associated complications such as liver dysfunction and cardiovascular disorders.

- Advancements in diagnostic techniques have led to better detection rates, increasing the reported prevalence of LAL-D.
- Greater awareness among healthcare professionals and patients is driving early diagnosis and treatment adoption.
- Kanuma plays a crucial role in addressing this condition by replacing the missing enzyme, reducing lipid accumulation, and preventing organ damage.

• A March 2023 report from the National Institutes of Health estimated LAL-D prevalence between 1:40,000 and 1:300,000, depending on ethnicity and region.

Who Are the Leading Players in the Kanuma Market?

AstraZeneca PLC is a key company operating in the Kanuma market, significantly influencing market trends and innovations.

What Are the Emerging Trends in the Kanuma Market?

A major trend shaping the Kanuma market is the increasing focus on enzyme replacement therapy (ERT), such as Kanuma, which helps manage LAL-D by restoring deficient enzyme levels.

• In November 2023, the National Health Service (NHS) highlighted the approval of sebelipase alfa (Kanuma) as the first treatment for Wolman disease available through NHS services.

• This approval followed a commercial agreement between NHS England and a recommendation from the National Institute for Health and Care Excellence (NICE), underscoring the growing support for rare disease treatments.

How Is the Kanuma Market Segmented?

The Kanuma market is categorized into the following segments:

1. By Indication: Treatment of Lysosomal Acid Lipase Deficiency, Treatment of Associated Conditions.

2. By Formulation: Injectable Formulation, Lyophilized Powder for Reconstitution.

3. By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients.

4. By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies.

5. By End User: Hospitals, Specialty Clinics, Home Healthcare Providers, Research Institutions.

Which Regions Hold the Largest Market Share for Kanuma?

• As of 2024, North America leads the Kanuma market in terms of revenue and market share.

• However, Asia-Pacific is forecasted to be the fastest-growing region during the upcoming period.

• The market report also encompasses other key regions, including Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse For More Similar Reports-

Antimicrobial Susceptibility Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antimicrobial-susceptibility-testingglobal-market-report

Synthetic Biology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/synthetic-biology-global-market-report Medical Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/medical-equipment-global-marketreport

Learn More About The Business Research Company

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info Follow Us On: LinkedIn: <u>https://in.linkedin.com/company/the-business-research-company</u> Twitter: <u>https://twitter.com/tbrc_info</u> YouTube: <u>https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ</u>

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook X LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/791970877

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.